- $95.73m
- $136.94m
- $164.46m
- 55
- 86
- 26
- 57
Annual income statement for Ultralife, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 108 | 98.3 | 132 | 159 | 164 |
| Cost of Revenue | |||||
| Gross Profit | 29.2 | 24.6 | 29.4 | 39.2 | 42.3 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 100 | 98.2 | 132 | 149 | 154 |
| Operating Profit | 7.29 | 0.035 | 0.129 | 9.47 | 9.96 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 7.02 | -0.151 | -0.446 | 9.12 | 8.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 5.33 | -0.23 | -0.12 | 7.17 | 6.41 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 5.23 | -0.234 | -0.119 | 7.2 | 6.31 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 5.23 | -0.234 | -0.119 | 7.2 | 6.31 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.25 | -0.015 | 0.024 | 0.448 | 0.445 |